Correlation of Neutrophil to Lymphocyte Ratio and Absolute Neutrophil Count With Outcomes With PD-1 Axis Inhibitors in Patients With Advanced Non–Small-Cell Lung Cancer
Alona Zer(Rambam Health Care Campus), Natasha B. Leighl(Princess Margaret Cancer Centre), Catherine Labbé(University Health Network), Dianne Zawisza(University Health Network), Manjula Maganti(Princess Margaret Cancer Centre), Melissa Iazzi(University Health Network), Leila Khoja(AstraZeneca (United Kingdom)), Frances A. Shepherd(University Health Network), Geoffrey Liu(Princess Margaret Cancer Centre), Preet Walia(University Health Network), Ronald Feld(University Health Network), Penelope A. Bradbury(University Health Network), Nazanin Nouriany(University Health Network)
Cited by 144
Related Papers
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
|Journal of Clinical Oncology|2004|2.4k
Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial
|The Lancet|2014|1.8k
Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|1.7k